J Gynecol Oncol.  2010 Jun;21(2):132-132. 10.3802/jgo.2010.21.2.132.

Proliferation of CD4(+)CD25(high+)Foxp3(+) regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma

• Jung YW
• Seong SJ
• Park CT

• KMID: 2009585
• DOI: http://doi.org/10.3802/jgo.2010.21.2.132

Abstract

No abstract available.

MeSH Terms

Ascitic Fluid
T-Lymphocytes, Regulatory

Reference

1. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006. 6:715–727.

2. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004. 10:942–949.

3. Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, Fujii S, et al. Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol. 2010. 116:556–562.

4. Lee SW, Kim YM, Lee HY, Kim DY, Kim JH, Nam JH, et al. Proliferation of CD4⁺CD25^high+Foxp3⁺ regulatory T lymphocytes in ex vivo expanded asciti fluid from primary and recurrent ovarian carcinoma. J Gynecol Oncol. 2010. 21:38–44.

5. Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, Sekine S, et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep. 2009. 22:273–278.

6. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010. 33:435–441.